Company / R&D Expense
LEXICON PHARMACEUTICALS, INC. R&D Expense History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$58.9M
FY2025
5-year range
$52.8M / $164.0M
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $59M.
Based on SEC 10-K filings.
$59M in FY2025 with a 10-year CAGR of -4.1%.
Improved from $55M to $59M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -4.1%
Key checks
Key Insights
- In FY2025, r&d expense increased 11.5% year-over-year.
- Peak r&d expense was recorded in FY2018.
- Lowest r&d expense in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.9M | +11.5% |
| FY2024 | $52.8M | -4.1% |
| FY2023 | $55.0M | -64.2% |
| FY2019 | $153.6M | -6.3% |
| FY2018 | $164.0M | +72.3% |
| FY2017 | $95.2M | +6.6% |
| FY2016 | $89.3M | -0.4% |
| FY2015 | $89.7M | +8.6% |
| FY2014 | $82.6M | -10.1% |
| FY2013 | $91.8M | +16.9% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026